ascopubs.org

Adjuvant chemotherapy with S-1 for patients with head and neck cancer after radical therapy: A phase I/II feasibility study.

Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses. Background: S-1 is a dihydropyrimidine dehydrogenase-inhibitor fluoropyrimidine, which showed a higher ...
Seeking Alpha

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients ...

KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) Results to be presented at American ...
ascopubs.org

Timely initiation of adjuvant therapy and survival in head and neck cancer: Post hoc analysis of the NDURE RCT.

Temporal trends in active surveillance and treatment strategies for low-risk, hormone receptor-positive ductal carcinoma in situ in the US. This is an ASCO Meeting Abstract from the 2025 ASCO Quality ...
Seeking Alpha

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

NEW YORK and VIENNA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (HOOK) (”HOOKIPA” or the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics ...